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Purpose

Because financial conflicts of interest (FCOIs) may potentially influence patient care, hospital drug
formularies, and treatment guidelines, it is important that these are disclosed. The purpose of this
observational study was to quantify the changes in FCOI among U.S.-based academic authors in
industry-sponsored oncology trials after a high-impact publication.

Methods

 list of all U.S.-based academic authors (authors) of industry-sponsored solid tumor clinical trials
A
published between August 1, 2014, and December 31, 2015, in 6 high-impact journals (New England
Journal of Medicine, Nature, Science, Lancet Oncology, Journal of Clinical Oncology, and Cancer
Discovery) was assembled. Studies were limited to solid tumor oncology trials. After all authors were
identified, direct and research funding was tabulated from CMS Open Payments for the year prior
(Ypre) and the first 3 years following publication (Y1, Y2, Y3) in the high-impact journal. Summary
statistics were tabulated and repeated-measures linear mixed-effects regression models were fit to
examine changes after publication.

Results

 total of 102 publications with a total of 620 authors were identified. No FCOI was declared by
A
11, 12, 21, and 24 authors in Ypre, Y1, Y2, and Y3, respectively. In Ypre, Y1, Y2, and Y3: median
FCOI for direct payments was $16,702 (range: $0–$3,180,356), $20,830 (range: $0–$3,180,356),
$22,031 (range: $0–$920,746), and $21,356 (range: $0–$920,707), respectively; while median
research funding was $559,202 (range: $0–$19,973,818), $505,031 (range $0–$19,920,452),
$502,726 (range: $0–$15,729,776), and $497,342 (range: $0–$43,036,716), respectively. There
were nonsignificant increases in total direct payments and total direct payments received from the
sponsor (P>0.0125 for both) and statistically significant decreases in total associated research
funding and total research funding from the research sponsor in Y1, Y2, and Y3 as compared to
Ypre (P<0.0001 for both).

Conclusions

 fter publication of an industry-sponsored solid tumor clinical trial in a high-impact journal, authors
A
had statistically significant decreases in research funding FCOI in the first 3 years postpublication
compared to the year prior. (J Patient Cent Res Rev. 2020;7:249-254.)
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inancial conflicts of interest (FCOIs) are known
to be prevalent across medical disciplines,
with the potential to influence hospital drug
formularies, treatment guidelines, meta-analyses,
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diagnostic criteria, and outcomes reporting.1-7
International findings report that FCOIs with drug
companies may influence drug recommendations and
are common among guideline-writing authors.8 FCOI
is a major area of concern in the field of oncology, as
it may introduce actions that bias clinical trial results,
reduce objectivity, and influence cancer treatment
recommendations.8-10 One-third of oncology authors
do not fully disclose all payments received from
the sponsor of the published clinical trial,10 which is
www.aah.org/jpcrr
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alarming considering the potential influence this may
have on the messaging within the trial publication.
The evidence presented in that oncology study is of
concern because other studies have reported at least
some degree of altered behavior whenever there is
interaction with drug companies.1-9 This can pose
negative consequences, including prescription of more
costly medication without additional benefit or with
marginal benefit of that treatment. Physicians also may
be blinded by unconscious bias from matching the
treatment most likely to benefit the patient.
To help improve transparency, a free online tool called
CMS Open Payments reports industry payments to
U.S.-based practitioners.11 Its limitations are that it is
restricted to companies that have activities in the United
States and have a drug or product in the United States that
is reimbursed by Children’s Health Insurance Program,
Medicare, or Medicaid. Thus, neophyte companies
sponsoring clinical trials that do not have a commercial
product or commercial test are not required to disclose
payments until a date after drug or test approval. Many
health centers have FCOI policies.12 However, few
promote complete transparency. The University of Texas
Southwestern Medical Center (Dallas, TX) allows public
access to its FCOI database. Washington University in
St. Louis (St. Louis, MO) publishes information on any
industry relationship that nets a physician more than
$10,000 annually on its medical practice website. Others,
such as Mayo Clinic (Rochester, MN) and Dana-Farber
Cancer Institute (Boston, MA) allow public access to
FCOIs upon request.
The primary objective of this observational research
analysis was to investigate if there was an increase
in direct payments or research funding to an author
subsequent to the year of publication of an oncology
clinical trial in a high-impact journal.

METHODS

Two independent reviewers searched for prospective
anticancer intervention studies that covered solid
tumors, were phase I–III clinical trials, and were
published (online or in print) in 1 of 6 high-impact
journals: New England Journal of Medicine, Nature,
Science, Lancet Oncology, Journal of Clinical
Oncology, and Cancer Discovery. The review was
conducted from July 2018 to December 2018, with
an update in December 2019 following journal peer
250 JPCRR • Volume 7, Issue 3 • Summer 2020

review. Only industry-sponsored trials were included.
Studies sponsored by national cancer agencies or
cooperative groups were excluded.
Once a study was identified, all of the listed authors
who met inclusion criteria were recorded in an Excel
spreadsheet. Authors had to be physicians based in the
United States, as the disclosure clause only applies to
practicing doctors. Authors had to be either an oncologist,
oncologic surgeon, dermatologist, or neuro-oncologist
who did not have an industry sponsor as their primary
affiliation. Pathologists, urologists, radiologists, and
radiation oncologists were excluded as these specialties
typically do not prescribe or administer systemic oral
or intravenous chemotherapy. Financial disclosure
information for all the identified authors was collected
from CMS Open Payments (https://www.cms.gov/
OpenPayments/Explore-the-Data/Dataset-Downloads.
html). All payments posted were considered FCOI.
Sponsor funding from related entities (eg, Genentech
and Genentech USA) was combined.
The financial information recorded included: total
direct payments, total associated research funding, total
direct payments received from the sponsor, and the total
research funding received from the research sponsor.
Total direct payment was defined as any payment
received by the author for a given year. Total associated
research funding for a given year was defined as all
research-related funding paid directly to the author or
to the author’s institution in support of studies for which
the author was the principal investigator. Total direct
payment received from the sponsor was defined as any
direct payments from the sponsor of the trial for which
the author was listed for a given year. Total research
funding received from the sponsor was any researchrelated funding paid to the author or the author’s
institution from the sponsor of the trial for which the
author was listed for a given year.
Data for these four categories were collected for the
365 days immediately preceding the publication date
(Ypre), day of publication up to 1 year postpublication
(Y1), end of Y1 to 2 years postpublication (Y2),
and end of Y2 to 3 years postpublication (Y3). Since
CMS Open Payment periods during this investigation
covered August 1, 2013, through December 31, 2018,
only e-publication or print publications posted between
August 1, 2014, and December 31, 2015, were included
Original Research

to allow for Y3 follow-up. Financial data from CMS
Open Payments was pulled and categorized as Ypre, Y1,
Y2, or Y3, respectively, relative to the publication date.
Distributions of the payment values were examined
and summary information (medians, means, minimum
and maximum values) presented. The distributions
were highly skewed, as is typical for this type of
data.13 To moderate the influence of extreme values,
logarithmic transformations of the outcome measures
were used to model the association with time period.
Reported payments of zero dollars were assigned
a logarithmic value of zero. This transformation
substantially reduced the skewness of the distributions.
Linear mixed-effects models were fit to the data. For
each outcome, the dependent variable of interest
was the logarithmic-transformed payment, treated as
repeated measures (ie, the four time periods), for each
author. The independent variable of interest was the
time period (as a categorical variable). The manuscript
was treated as a random effect in the model. An
autoregressive covariance structure was used, as it fit
the data better than compound symmetry based on the
Akaike information criterion.14
For each model, the estimated percentage change in
payments for Y1, Y2, and Y3 relative to Ypre is reported,
along with the corresponding 95% confidence interval.
A P-value comparing the three postpublication time
periods also is reported. To preserve a global 5% level of
significance, a Bonferroni approach was implemented
and P-values less than 0.0125 were considered
statistically significant. The Bonferroni approach is a
standard statistical method for preserving a global level
of significance (ie, false-positive rate and α) for a study

that includes multiple statistical tests. In this case, we
wanted to limit the probability of a false-positive result
to 0.05 across 4 statistical tests, so we set the level of
significance to 0.0125 (ie, 0.05/4) for each test.

RESULTS

A total of 102 publications with a total of 620 authors
were identified (complete data set available from
corresponding author by request). No FCOI was
declared by 11, 12, 21, and 24 authors in Ypre, Y1,
Y2, and Y3, respectively. In Ypre, Y1, Y2, and Y3,
respectively, the median FCOI for direct payments
was $16,702 (range: $0–$3,180,356), $20,830 (range:
$0–$3,180,356), $22,031 (range: $0–$920,746), and
$21,356 (range: $0–$920,707). In Ypre, Y1, Y2, and
Y3, respectively, the median research funding was
$559,202 (range: $0–$19,973,818), $505,031 (range:
$0–$19,920,452), $502,726 (range: $0–$15,729,776),
and $497,342 (range: $0–$43,036,716).
Results of the regression models are shown in Tables
1 and 2. There were increases in total direct payments
(P=0.024) and total direct payments received from the
sponsor (P=0.033) in Y1, Y2, and Y3 as compared
to Ypre, though these increases did not reach the
prespecified threshold for statistical significance of
P<0.0125. Total associated research funding and total
research funding from the research sponsor were
significantly decreased in Y1, Y2, and Y3 compared
to Ypre (P<0.0001 for both). Relative to Ypre, direct
payments increased by 26.4% in Y1, 25.2% in Y2, and
8% in Y3, while total direct payments received from
the sponsor increased by 32.9% in Y1, 40.5% in Y2,
and 12.4% in Y3. Relative to Ypre, total associated
research funding decreased by 9.1% in Y1, 30.9% in

Table 1. Regression Model* Results
Outcome
Measure

Direct
payments

Research
funding

Direct payments
from sponsor

Research funding
from sponsor

Y1 percentage change

26.4 (7.5, 48.7)

-9.1 (-23.5, 7.9)

32.9 (5.9, 66.7)

-32.0 (-49.0, -9.4)

Y2 percentage change

25.2 (2.4, 52.9)

-30.9 (-44.1, -14.4)

40.5 (7.1, 84.4)

-60.8 (-72.4, -44.5)

Y3 percentage change

8.0 (-12.1, 32.7)

-47.6 (-57.9, -34.7)

12.4 (-14.6, 47.9)

-72.0 (-80.4, -60.0)

0.024

<0.0001

0.033

<0.0001

P-value

*A repeated measures, linear mixed-effects model with time point as a fixed effect and manuscript as a random effect. The
outcome measures were logarithmic transformations. Percentage changes (with confidence interval in parentheses) are relative
to the year prior to publication. The P-value tests whether the three time periods had equal payments.
Original Research
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Table 2. Mean and Median Values for Each FCOI Category
Mean ± SD

Median (Q1–Q3)

$45,338 ± $207,813
$42,859 ± $138,427
$42,989 ± $74,973
$44,405 ± $78,549

$16,702 ($2802–$41,430)
$20,829 ($4368–$44,928)
$22,031 ($4751–$51,980)
$21,356 ($3887–$50,959)

$1,149,739 ± $1,951,608
$1,230,219 ± $2,185,201
$1,093,947 ± $1,715,387
$1,162,986 ± $2,313,992

$559,203 ($133,175–$1,377,822)
$505,031 ($128,641–$1,506,445)
$502,726 ($115,240–$1,344,879)
$497,342 ($72,059–$1,419,730)

$14,301 ± $171,260
$6587 ± $26,076
$5525 ± $12,586
$4642 ± $10,948

$0 ($0–$3944)
$0 ($0–$4508)
$0 ($0–$5867)
$0 ($0–$4867)

   Ypre

$199,030 ± $473,630

$8189 ($0–$182,849)

   Y1

$213,880 ± $641,705

$2865 ($0–$149,810)

   Y2
   Y3

$152,262 ± $629,739
$225,868 ± $1,712,224

$237 ($0–$113,998)
$0 ($0–$88,714)

Direct payments
   Ypre
   Y1
   Y2
   Y3
Research funding
   Ypre
   Y1
   Y2
   Y3
Direct payments from sponsor
   Ypre
   Y1
   Y2
   Y3
Research funding from sponsor

FCOI, financial conflict of interest; Q1, 25th percentile; Q3, 75th percentile; SD, standard deviation; Ypre, the time period 365
days immediately preceding publication date; Y1, day of publication to 1 year postpublication; Y2, second year after publication;
Y3, third year after publication.

Y2, and 47.6% in Y3, while total associated research
funding from the research sponsor decreased by 32%
in Y1, 60.8% in Y2, and 72% in Y3.

DISCUSSION

Ethically speaking, FCOIs may have a negative
effect on research and publication. They can, perhaps
unconsciously, bias moral judgment when developing
arguments in an area of scientific or clinical research
or regarding health policy.15 FCOIs also are of
great clinical significance due to their potential to
influence a physician’s choice in therapy. Physicians
who occasionally accepted a sponsored meal from a
pharmaceutical company were 2 to 3 times more likely
to request that drug company’s product be placed on a
hospital’s drug formulary.16
The data presented herein show an ongoing financial
relationship between sponsors and authors after
publication. Some examples of ongoing relationships
may include serving on speaker’s bureaus or advisory
252 JPCRR • Volume 7, Issue 3 • Summer 2020

boards, participation in investigator’s meetings, or
serving as investigators on future trials. While it may
seem intuitive that increased accrual and funding to
the institution go hand in hand with the conduct and
oversight of a clinical trial, this study did not just look at
institutional funding. It also incorporated the aggregation
of total direct payments, which includes promotional
speaking and/or consulting from sources that are required
to report to CMS Open Payments. It is important to note
that when self-reporting their FCOI, nearly two-thirds
of oncologists have discordant disclosures between a
clinical trial abstract and the subsequent full manuscript
publication of that clinical trial.17 The prevalence of
FCOI discordance is maintained among authors in
American Society of Clinical Oncology publications
and/or conference presentations and their associated
disclosures posted on CMS Open Payments.18
We chose to analyze solid tumors, as this is the
primary focus of medical oncology. Treatment for
medical oncology patients is primarily administered
Original Research

in outpatient clinics and/or standalone cancer centers
and is the expertise of one of the authors. In contrast,
hematologists specializing in the treatment of patients
with hematologic malignancies more commonly
administer treatment in an inpatient setting. This
difference in care delivery would likely result in
differences in direct payments and research funding.
After publication of an industry-sponsored solid
tumor clinical trial in a high-impact journal, authors
had nonsignificant increases in FCOI (direct payments
and sponsor of trial direct payments). Surprisingly,
there were significant decreases in research funding
and sponsor of trial research funding FCOI in the first
3 years postpublication compared to the year prior.
Several possibilities could explain this decrease in
research funding for the identified authors in this
analysis. These include but are not limited to: 1)
diminished research funding due after publication
of the high-impact study; 2) identified authors may
not be the lead investigators for their institution in
subsequent studies that incur research funding; 3)
the identified authors may have decreased their
research activities; or 4) the identified authors are
lead investigators on studies with sponsors that do
not meet the criteria for reporting payments to CMS
Open Payments.
Other areas for future exploration include examining
FCOI changes before and after a pivotal trial among
authors outside of oncology. Are those changes
commensurate with the relationships observed in
medical oncology? What areas of oncology research
do we observe peaks and valleys of FCOI over time?
Limitations
There are some limitations of our study. Research
funding to the author institutions could be delayed
and fall on the years subsequent to the publication
and influence the results. In addition, funding may be
underreported from companies that are exempt from
CMS Open Payment reporting. Nearly 10% of authors
had no funding in CMS Open Payments during one of
the time points, and a small fraction of authors were
outliers with significant funding. Thus, to alleviate the
skewness, logarithmic transformation was required.
The linear mixed-effects model essentially looks at the
change in logarithmic payments from Ypre to Y1 to
Y2 to Y3 for each author and averages those changes
Original Research

across the authors. If increases were only happening
for a small subset of the authors, the differences would
not be statistically significant. Due to small numbers
and potential limitations of multiple hypothesis
testing, we did not perform additional analyses with
respect to the number of funding sources, primary
endpoint of trial being met, or the author position on
the publication. Other limitations of the CMS Open
Payments database include the potential inaccuracy
of FCOI reporting attributed to a physician and short
deadlines to remedy an error. If no FCOI is declared in
the CMS Open Payments database, this means that the
investigator has no FCOI that qualifies for reporting in
the database. These investigators still may have FCOI
with entities that are not legally required to report,
but those influences on hospital drug formulary and
treatment guidelines are minimal or unlikely to be
relevant at the time of the publication.
A potential remedy to more accurately reflect FCOI
would be for journals to require, upon acceptance of
a manuscript, that authors with social media profiles
provide a link to their FCOI or declare it in their
announcements or “likes” to links related to their
publication or subsequent sponsor-related talks/
promotions for a period of 24 months postpublication.19
Another option would be to make the contracts between
authors and industry sponsors available to the public.

CONCLUSIONS

The purpose of this observational study was to
report if there was an increase in direct payments or
research funding to an author subsequent to the year
of publication of an oncology clinical trial in a highimpact journal. We observe that authors of industrysponsored solid tumor clinical trials published in
high-impact journals had statistically significant
decreases in research funding FCOI in the first 3 years
postpublication compared to the year prior.
There are various studies that demonstrate that FCOIs
between industry and physicians have influenced
physician behavior and patient care, either directly or
indirectly. FCOIs should be disclosed and managed,
ideally in a uniform and transparent manner. Overall,
there remains a number of unanswered questions and
opportunities to further explore, not just in oncology,
but within and across other medical disciplines.
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Patient-Friendly Recap
• Financial conflicts of interest have the
potential to influence the work of physicians
and researchers. Thus, in the United States,
lead investigators of clinical trials must
disclose these relationships.
• The authors analyzed disclosures from a
federal database to determine if payments
to oncology investigators or their institutions
changed substantially after results from major
clinical trials had been published.
• The authors found that research funding to
these investigators actually decreased in the
3 years following publication, and they offer
possible explanations for their findings.
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